First Wave BioPharma, Inc. is a clinical stage biopharmaceutical company based in Boca Raton, FL, specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. Their product portfolio includes capeserod, a selective 5-HT4 receptor partial agonist, adrulipase, a recombinant lipase enzyme, and niclosamide, an oral small molecule with anti-inflammatory properties. With a focus on GI indications, their pipeline encompasses various clinical indications, ranging from nutritional disorders to diseases caused by immune malfunction, targeting patient populations with digestive disorders and inflammatory bowel diseases.
First Wave BioPharma's innovative approach to developing therapies for GI diseases has garnered attention in the industry. Their commitment to advancing research and addressing unmet medical needs is evident in their pursuit of effective treatments for conditions such as exocrine pancreatic insufficiency, cystic fibrosis, chronic pancreatitis, ulcerative colitis, and Crohn's disease. Through their proprietary technologies and clinical expertise, First Wave BioPharma aims to make a significant impact on the lives of patients suffering from GI disorders.
Generated from the website
